Journal Home
Search for

Volume 172, Issue 5, Supplement, Pages S28-S33 (November 2004)


View previous. 8 of 17 View next.

PREDICTING PROSTATE CANCER BEHAVIOR USING TRANSCRIPT PROFILES

PETER S. NELSONCorresponding Author Informationemail address

ABSTRACT 

Purpose

Prostate cancer represents a disease with diverse clinical outcomes. Treatment strategies that optimize benefit and minimize morbidities depend on accurate estimates of disease status and likelihood of progression. Emerging technologies capable of qualitatively and quantitatively profiling genes expressed by neoplastic tissues may provide insights into tumor behavior. This review discusses the use of microarray based transcript expression profiling to stratify human cancers into risk categories.

Materials and Methods

MEDLINE was used to perform a comprehensive literature review of reports describing the assessment of gene expression profiles in malignant diseases. Particular emphasis was placed on studies developing models using individual genes or gene cohorts as predictors of prostate cancer outcome.

Results

Alterations in the expression of individual genes identified by microarray analyses have been used in studies of outcome in cancers of the prostate and other tissue types. Profiles of expressed genes have been used to develop prediction models that stratify cancers into prognostic categories based on relapse rates or responses to therapy.

Conclusions

Gene expression profiles offer an opportunity for acquiring molecular determinants correlating with clinical outcome. With rare exceptions these profiles have yet to be validated or used in prospective studies. Future research will benefit from assessments of intratumor heterogeneity and host factors such as the immune response and hormonal milieu. The prospective validation of predictive models will serve to prove usefulness in the clinical arena.

From the Fred Hutchinson Cancer Research Center, Seattle, Washington

Corresponding Author InformationCorrespondence: Divisions of Human Biology and Clinical Research, Mailstop D4-100, 1100 Fairview Ave. North, Seattle, Washington 98109

 Supported by National Cancer Institute SPORE Grant CA97186.

PII: S0022-5347(05)61304-3

doi:10.1097/01.ju.0000142067.17181.68


View previous. 8 of 17 View next.